STX-478 for Healthy Subjects
Trial Summary
What is the purpose of this trial?
The main purpose of this study is to conduct blood tests to measure how much STX-478 is in the bloodstream and how the body handles and eliminates it in healthy participants. This study will involve a single dose of 14C radiolabeled STX-478. This means that a radioactive tracer substance, C14, will be incorporated into the study drug STX-478 to investigate the study drug and its breakdown products and to find out how much of these passes from blood into urine, feces and expired air. The study will also evaluate the safety and tolerability of STX-478.
Research Team
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Eligibility Criteria
This trial is for healthy male participants with a BMI between 18.0 and 32.0 kg/m2, weighing between 55.0 and 100.0 kg, who are non-smokers (including no nicotine use within the last six months). They must test negative for hepatitis B, C, and HIV.Inclusion Criteria
Treatment Details
Interventions
- [14C]-STX-478 (Radiopharmaceutical)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University
Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
Lead Sponsor